Research Reference
BPC-157
Gut, tendon, and ligament healing — the recovery peptide
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a protein found in human gastric juice. It is one of the most researched healing peptides, with hundreds of animal studies documenting effects on tissue repair, gut healing, tendon recovery, and neuroprotection. No human clinical trials exist.
Community-reported protocols most commonly describe 500 mcg once daily for 8 weeks, then 8 weeks off. Some users split the dose AM/PM (250 mcg twice daily) for more consistent tissue levels, but the total daily dose stays at 500 mcg.
Side Effects & Safety
- No lethal dose found — toxicology studies could not establish an LD50 (Sikiric et al., 2006)
- No organ toxicity in chronic dosing
- No hormonal effects — does not affect testosterone, estrogen, cortisol, or GH
- Mild nausea — mostly with oral dosing
- Brief lightheadedness — occasionally after injection
- Injection site redness — standard for subcutaneous peptides
No human clinical trials exist; all safety data comes from animal studies and community self-reports.
Research Basis
Community doses are extrapolated from a large body of animal research.
Animal study doses: Nearly all BPC-157 research uses rats at 10 mcg/kg (the standard research dose), with some studies up to 50 mcg/kg, across hundreds of studies (Sikiric et al., 2006; Krivic et al., 2006).
Allometric scaling: Using the FDA's standard body surface area conversion (rat dose × 0.162), the human equivalent range is roughly 110–560 mcg/day — which is where the community's 250–500 mcg/day window comes from.
Wide therapeutic window: Animal studies showed activity even at ultra-low doses (10 ng/kg), suggesting BPC-157 is active across a broad dose range (Krivic et al., 2006).